Movement Alert｜AstraZeneca Falls 6.39% Overnight, Market Weighs Aggressive Deal Spending Including $2.1 Billion China Drug License

Market Focus

Jul 09

On July 9, AstraZeneca fell 6.39% overnight, trading at $177.19 USD/share, with turnover of $387,400 in thin overnight conditions.

The decline followed AstraZeneca's announcement of a deal worth up to $2.1 billion with Sino Biopharmaceutical's unit Chia Tai Tianqing for exclusive rights to develop, manufacture, and commercialize the COPD drug candidate TQC3721 outside China. The agreement includes a $200 million upfront payment and up to $1.9 billion in development, regulatory, and sales milestones. This transaction came just days after a $1.77 billion siRNA collaboration with CSPC Pharmaceutical, raising market concerns over AstraZeneca's pace of capital deployment on early-to-mid-stage assets.

Within the Pharmacy sector, peers remained broadly flat: Eli Lilly up 0.01%, Pfizer up 0.21%, Merck up 0.17%, Johnson & Johnson down 0.08%, and Crinetics Pharmaceuticals unchanged, underscoring AstraZeneca's move as company-specific. The company's next earnings report is scheduled for July 27.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1149087014"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1149087014\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1149087014?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-09 15:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1149087014","market":"hk","top_or_hot":-1,"title":"Movement Alert｜AstraZeneca Falls 6.39% Overnight, Market Weighs Aggressive Deal Spending Including $2.1 Billion China Drug License","media":"Market Focus","content":"<p><p>On July 9, AstraZeneca fell 6.39% overnight, trading at $177.19 USD/share, with turnover of $387,400 in thin overnight conditions.</p><p>The decline followed AstraZeneca's announcement of a deal worth up to $2.1 billion with Sino Biopharmaceutical's unit Chia Tai Tianqing for exclusive rights to develop, manufacture, and commercialize the COPD drug candidate TQC3721 outside China. The agreement includes a $200 million upfront payment and up to $1.9 billion in development, regulatory, and sales milestones. This transaction came just days after a $1.77 billion siRNA collaboration with CSPC Pharmaceutical, raising market concerns over AstraZeneca's pace of capital deployment on early-to-mid-stage assets.</p><p>Within the Pharmacy sector, peers remained broadly flat: Eli Lilly up 0.01%, Pfizer up 0.21%, Merck up 0.17%, Johnson & Johnson down 0.08%, and Crinetics Pharmaceuticals unchanged, underscoring AstraZeneca's move as company-specific. The company's next earnings report is scheduled for July 27.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜AstraZeneca Falls 6.39% Overnight, Market Weighs Aggressive Deal Spending Including $2.1 Billion China Drug License</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜AstraZeneca Falls 6.39% Overnight, Market Weighs Aggressive Deal Spending Including $2.1 Billion China Drug License\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-09 15:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 9, AstraZeneca fell 6.39% overnight, trading at $177.19 USD/share, with turnover of $387,400 in thin overnight conditions.</p><p>The decline followed AstraZeneca's announcement of a deal worth up to $2.1 billion with Sino Biopharmaceutical's unit Chia Tai Tianqing for exclusive rights to develop, manufacture, and commercialize the COPD drug candidate TQC3721 outside China. The agreement includes a $200 million upfront payment and up to $1.9 billion in development, regulatory, and sales milestones. This transaction came just days after a $1.77 billion siRNA collaboration with CSPC Pharmaceutical, raising market concerns over AstraZeneca's pace of capital deployment on early-to-mid-stage assets.</p><p>Within the Pharmacy sector, peers remained broadly flat: Eli Lilly up 0.01%, Pfizer up 0.21%, Merck up 0.17%, Johnson & Johnson down 0.08%, and Crinetics Pharmaceuticals unchanged, underscoring AstraZeneca's move as company-specific. The company's next earnings report is scheduled for July 27.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AZN","symbol_name":"阿斯利康","start_time":0,"source_url":"","article_id":"1149087014","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1149087014","pubTimestamp":1783580693,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 9, AstraZeneca fell 6.39% overnight, trading at $177.19 USD/share, with turnover of $387,400 in thin overnight conditions.The decline followed AstraZeneca's announcement of a deal worth up to...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AZN":"阿斯利康"},"translate_title":"动向提示|阿斯利康隔夜跌6.39%市场权衡激进交易支出包括21亿美元中国药品许可","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":1},"content_text":"On July 9, AstraZeneca fell 6.39% overnight, trading at $177.19 USD/share, with turnover of $387,400 in thin overnight conditions.The decline followed AstraZeneca's announcement of a deal worth up to $2.1 billion with Sino Biopharmaceutical's unit Chia Tai Tianqing for exclusive rights to develop, manufacture, and commercialize the COPD drug candidate TQC3721 outside China. The agreement includes a $200 million upfront payment and up to $1.9 billion in development, regulatory, and sales milestones. This transaction came just days after a $1.77 billion siRNA collaboration with CSPC Pharmaceutical, raising market concerns over AstraZeneca's pace of capital deployment on early-to-mid-stage assets.Within the Pharmacy sector, peers remained broadly flat: Eli Lilly up 0.01%, Pfizer up 0.21%, Merck up 0.17%, Johnson & Johnson down 0.08%, and Crinetics Pharmaceuticals unchanged, underscoring AstraZeneca's move as company-specific. The company's next earnings report is scheduled for July 27.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}